Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV8-hCocH
- Development stage
- Phase 1
- Lead developer
- Mayo Clinic
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
AAV8-hCocH is a gene therapy being developed for cocaine use disorder. It's an adeno-associated viral vector (AAV8) that encodes a modified plasma enzyme called human cocaine hydrolase (hCocH). This enzyme metabolizes cocaine into harmless by-products, potentially reducing the pleasurable effects of cocaine and helping individuals maintain abstinence. The therapy is administered intravenously, with the vector primarily targeting the liver. By breaking down cocaine in the body, it may reduce the pleasurable effects of the drug, decrease craving, and help prevent relapse in individuals seeking to abstain from cocaine use.
Beyond the preview
Go deeper on AAV8-hCocH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV8-hCocH.